快速起效抗抑郁药在iPSC来源神经元中的时间依赖效应
该研究将难治性抑郁(TRD)患者与健康志愿者的iPSC分化为成熟皮层样神经元,并用(2R,6R)-HNK、裸盖菇素、LSD和DOI处理6小时与24小时。批量与单细胞RNA测序显示,各化合物在匹配时间点的整体基因表达高度相关,共同汇聚于炎症、mTORC1信号与细胞生长通路;(2R,6R)-HNK呈现兴奋性神经元上调、抑制性神经元下调的细胞类型特异性改变,并与氯胺酮处理健康人CSF蛋白质组特征重叠。
要点
- 不同药理靶点的快速起效抗抑郁药在iPSC神经元中呈现高度相关的整体转录反应。
- 谷氨酸能与5-羟色胺能药物共同汇聚于炎症、mTORC1信号与细胞生长通路。
- (2R,6R)-HNK的差异表达基因与氯胺酮处理健康人CSF蛋白质组特征重叠。
核心结论
- 尽管各化合物初始药理靶点不同,其在匹配时间点的整体基因表达高度相关,提示存在共享的下游效应。
- (2R,6R)-HNK在单细胞水平呈兴奋性神经元上调与抑制性神经元下调的细胞类型特异性改变。
研究设计与样本
- 研究将TRD患者与健康志愿者的iPSC分化为成熟皮层样神经元,并用(2R,6R)-HNK、裸盖菇素、LSD与DOI处理6小时和24小时。
- 采用批量与单细胞RNA测序评估整体及细胞类型特异性转录组反应,并用Western blotting与免疫细胞化学评估突触蛋白。
- 将转录组结果与氯胺酮处理健康人的CSF蛋白质组比较以验证转化相关性;临床试验注册号NCT02484456。
主要发现
- 所有化合物在匹配时间点与溶剂对照相比整体基因表达高度相关,提示共享下游效应。
- 谷氨酸能与5-羟色胺能药物均汇聚于涉及炎症、mTORC1信号与细胞生长的通路。
- (2R,6R)-HNK处理神经元的差异表达基因与氯胺酮处理个体的CSF蛋白质组特征重叠。
临床怎么用
- 该研究支持人iPSC来源神经元用于抗抑郁药发现,并提示可依据共享下游通路与细胞类型特异性反应评估候选药物。
- (2R,6R)-HNK转录组与氯胺酮CSF蛋白质组特征的重叠可作为转化相关性的参考依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rapid-acting antidepressants like ketamine and serotonergic psychedelics show promise for treatment-resistant depression (TRD), but the molecular mechanisms that contribute to their therapeutic effects remain unclear. Induced pluripotent stem cells (iPSCs) offer a platform to model human cortical neurons and investigate drug effects in a human-relevant system. Here, iPSCs from individuals with TRD and healthy volunteers (HVs) were differentiated into mature cortical-like neurons and treated for six and 24 h with agents being investigated as rapid-acting antidepressants, including (2 R,6 R)-hydroxynorketamine (HNK), psilocybin, lysergic acid diethylamide (LSD), and 2,5-Dimethoxy-4-iodoamphetamine (DOI). Bulk and single-cell RNA sequencing assessed global and cell-type-specific transcriptomic responses. Synaptic proteins were evaluated via Western blotting and immunocytochemistry. To validate translational relevance, transcriptomic results were compared to CSF proteomics from ketamine-treated HVs. Despite differing initial pharmacological targets, overall gene expression across all compounds was highly correlated at matched timepoints compared to vehicle control, suggesting shared downstream effects. Both glutamatergic and serotonergic drugs converged on pathways involving inflammation, mTORC1 signaling, and cellular growth. At the single-cell level, (2 R,6 R)-HNK showed distinct cell-type specific alterations: upregulation in excitatory neurons and concomitant downregulation of inhibitory neuron populations. Differentially expressed genes from (2 R,6 R)-HNK-treated neurons also overlapped with CSF proteomic signatures from ketamine-treated individuals, supporting the model's translational relevance. This study is the first to assess multiple putative rapid-acting antidepressants in parallel using an iPSC-derived neuron model. Both convergent and drug-specific changes in gene expression and pathway enrichment were observed across diverse compounds, supporting the use of human iPSC-derived neurons in antidepressant drug discovery. Clinical Trial Registry: www.clinical trials.gov, NCT02484456.
引用
- Johnston JN, Jones GH, Peng S, et al. Time-dependent effects of rapid-acting antidepressants in iPSC-derived neurons from treatment-resistant depression and healthy volunteers. Mol Psychiatry. 2026. PMID: 42498781. doi:10.1038/s41380-026-03768-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。